Article

Generic Combination Antiplatelet Agent Launches in US

Author(s):

Teva has launched a generic version of aspirin and extended-release dipyridamole (Aggrenox) capsules in the United States.

Teva has launched a generic version of aspirin and extended-release dipyridamole (Aggrenox) capsules in the United States.

This combination antiplatelet agent is indicated to reduce the risk of stroke in patients who have previously experienced a transient ischemic attack or stroke due to thrombosis.

One American dies from a stroke every 4 minutes, on average. Of the 800,000 Americans who experience a stroke annually, 25% had a previous stroke.

“Teva recognizes the devastating impact of a stroke and is pleased to launch generic aspirin and extended-release dipyridamole capsules as a treatment option for at-risk stroke patients,” stated Brendan O’Grady, president and CEO of North America Generic Medicines for Teva.

This product is contraindicated in patients with known hypersensitivity to aspirin or dipyridamole, those with known allergy to nonsteroidal anti-inflammatory drugs, and patients with asthma, rhinitis, and nasal polyps.

The most frequently reported adverse reactions to aspirin and extended-release dipyridamole capsules in a placebo-controlled clinical study were headache, dyspepsia, abdominal pain, nausea, and diarrhea.

As of April 2015, Aggrenox had annual sales of about $457 million in the United States, according to IMS data.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com